On June 18, 2025 Cebiotex reported that the clinical trial to evaluate the safety, pharmacokinetics and efficacy of CEB-01 in locally resectable abdominal tumours of children has been green lighted by the regulatory authorities (Press release, Cebiotex, JUN 18, 2025, View Source [SID1234653973]). This is a basket trial designed for pediatric patients under 18 years of age diagnosed with de novo or recurrent soft tissue sarcoma, neuroblastoma, or other rare tumors such as Wilms’ tumor or germ cell tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Why it matters
It marks the first time that the potent active substance SN-38 is being evaluated in these patients as a local chemotherapy, with the goal of controlling tumor recurrence and addressing an unmet medical need. This step brings us closer to delivering new therapeutic options to children with rare cancers.

Thank You
This milestone reflects the commitment to developing innovative surgical treatments for children of our team and collaborators in Hospital Sant Joan de Déu Barcelona, i4KIDS I i4KIDS-EUROPE and Ship2B Ventures.